ERNA
Eterna Therapeutics Inc
NASDAQ: ERNA · HEALTHCARE · BIOTECHNOLOGY
$12.14
-12.28% today
Updated 2026-06-02
Market cap
$9.20M
P/E ratio
0.01
P/S ratio
1,275.37x
EPS (TTM)
$1,214.25
Dividend yield
—
52W range
$3 – $75
Volume
2.4M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D6.5
Quality
B3.0
Profitability
D5.7
Valuation
C+4/9
Piotroski F-Score
Moderate
-66.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$30.00
+147.12%
12-Month target
—
—
Intrinsic (DCF)
$0.22
Margin of safety
-37.32%
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.06x — low leverage
Risks
- Altman Z -66.50 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.27M
- Revenue declining -94.10% QoQ
- 37.32% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $68000.00 | $582000.00 | $0.00 | $1000.00 |
| Net income | $-24.58M | $-21.67M | $-44.54M | $-14.08M | $-5.51M |
| EPS | — | — | — | — | $1,214.25 |
| Free cash flow | $-21.27M | $-20.43M | $-16.20M | $-7.05M | $-2.27M |
| Profit margin | — | -31,864.71% | -7,652.75% | — | — |
Peer comparison
Smart narrative
Eterna Therapeutics Inc trades at $12.14. representing a P/E of 0.01x trailing earnings. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -66.50, it sits in the distress. TTM revenue stands at $1000.00. Our DCF model estimates intrinsic value at $0.22.
Frequently asked questions
What is Eterna Therapeutics Inc's stock price?
Eterna Therapeutics Inc (ERNA) trades at $12.14, on a P/E of 0.0x and a P/S of 1,275.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Eterna Therapeutics Inc overvalued?
Eterna Therapeutics Inc carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $0.22 against the $12.14 price, so on cash flow terms the market is paying a premium for Eterna Therapeutics Inc's growth. The Strong Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Eterna Therapeutics Inc (ERNA)?
The 12-month analyst consensus target is $30.00, about 147.1% above the current $12.14. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Eterna Therapeutics Inc (ERNA)?
Our DCF model estimates intrinsic value at $0.22, a -37.3% margin of safety versus today's $12.14. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Eterna Therapeutics Inc's revenue?
Eterna Therapeutics Inc's trailing twelve-month revenue is $1000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Eterna Therapeutics Inc's Altman Z-Score is -66.50, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1,275.37x
ROE-166.02%
Beta1.89
50D MA$7.02
200D MA$22.46
Shares out0.00B
Float0.00B
Short ratio—
Avg volume2.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—